Tetsuya Kamataki

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Murai K; Yamazaki H; Nakagawa K; Kawai R; Kamataki T
Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes.
Matsunaga Masayuki; Yamazaki Hiroshi; Kiyotani Kazuma; Iwano Shunsuke; Saruwatari Jyunji; Nakagawa Kazuko; Soyama Akiko; Ozawa Shogo; Sawada Jun-Ichi; Kashiyama Eiji; Kinoshita Moritoshi; Kamataki Tetsuya
Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
Uno Yasuhiro; Ohuchi Tsukasa; Uehara Shotaro; Kito Go; Kamataki Tetsuya; Nagata Ryoichi
Sex-related differences in the expression of mfGSTA2, a novel GST identified in cynomolgus monkey (Macaca fascicularis).

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Tetsuya Kamataki (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Murai K; Yamazaki H; Nakagawa K; Kawai R; Kamataki T
Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes.
Xenobiotica; the fate of foreign compounds in biological systems 2009;39(11):795-802.
2009: Matsunaga Masayuki; Yamazaki Hiroshi; Kiyotani Kazuma; Iwano Shunsuke; Saruwatari Jyunji; Nakagawa Kazuko; Soyama Akiko; Ozawa Shogo; Sawada Jun-Ichi; Kashiyama Eiji; Kinoshita Moritoshi; Kamataki Tetsuya
Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(4):699-701.
2009: Uno Yasuhiro; Ohuchi Tsukasa; Uehara Shotaro; Kito Go; Kamataki Tetsuya; Nagata Ryoichi
Sex-related differences in the expression of mfGSTA2, a novel GST identified in cynomolgus monkey (Macaca fascicularis).
Drug metabolism and disposition: the biological fate of chemicals 2009;37(3):453-6.
2009: Kuribayashi Shunji; Goto Kiyoto; Naito Shinsaku; Kamataki Tetsuya; Yamazaki Hiroshi
Human cytochrome P450 1A2 involvement in the formation of reactive metabolites from a species-specific hepatotoxic pyrazolopyrimidine derivative, 5-n-butyl-7-(3,4,5-trimethoxybenzoylamino)pyrazolo[1,5-a]pyrimidine.
Chemical research in toxicology 2009;22(2):323-31.
2008: Fujita Ken-ichi; Yamamoto Wataru; Endo Shoji; Endo Hisashi; Nagashima Fumio; Ichikawa Wataru; Tanaka Ryuhei; Miya Toshimichi; Araki Kazuhiro; Kodama Keiji; Sunakawa Yu; Narabayashi Masaru; Miwa Keisuke; Ando Yuichi; Akiyama Yuko; Kawara Kaori; Kamataki Tetsuya; Sasaki Yasutsuna
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Cancer science 2008;99(5):1049-54.
2007: Uno Yasuhiro; Hosaka Shinya; Matsuno Kiyomi; Nakamura Chika; Kito Go; Kamataki Tetsuya; Nagata Ryoichi
Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism?
Archives of biochemistry and biophysics 2007;466(1):98-105.
2007: Matsuda Yoko; Saoo Kousuke; Yamakawa Keiko; Yokohira Masanao; Suzuki Satoshi; Kuno Toshiya; Kamataki Tetsuya; Imaida Katsumi
Overexpression of CYP2A6 in human colorectal tumors.
Cancer science 2007;98(10):1582-5.
2007: Matsuda Yoko; Yamakawa Keiko; Saoo Kousuke; Hosokawa Kyoko; Yokohira Masanao; Kuno Toshiya; Iwai Junko; Shirai Takatoshi; Obika Kaoru; Kamataki Tetsuya; Imaida Katsumi
CYP2A6 overexpression in human lung cancers correlates with a high malignant status.
Oncology reports 2007;18(1):53-7.
2007: Mitani Yasumasa; Lezhava Alexander; Kawai Yuki; Kikuchi Takeshi; Oguchi-Katayama Atsuko; Kogo Yasushi; Itoh Masayoshi; Miyagi Toru; Takakura Hideki; Hoshi Kanako; Kato Chiaki; Arakawa Takahiro; Shibata Kazuhiro; Fukui Kenji; Masui Ryoji; Kuramitsu Seiki; Kiyotani Kazuma; Chalk Alistair; Tsunekawa Katsuhiko; Murakami Masami; Kamataki Tetsuya; Oka Takanori; Shimada Hiroshi; Cizdziel Paul E; Hayashizaki Yoshihide
Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology.
Nature methods 2007;4(3):257-62.
2007: Uno Y; Kumano T; Kito G; Nagata R; Kamataki T; Fujino H
CYP2C76-mediated species difference in drug metabolism: a comparison of pitavastatin metabolism between monkeys and humans.
Xenobiotica; the fate of foreign compounds in biological systems 2007;37(1):30-43.
2007: Yamazaki Hiroshi; Fujita Haruka; Gunji Takaaki; Zhang Jun; Kamataki Tetsuya; Cashman John R; Shimizu Makiko
Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population.
Molecular genetics and metabolism 2007;90(1):58-63.
2006: Peamkrasatam Sompop; Sriwatanakul Kampon; Kiyotani Kazuma; Fujieda Masaki; Yamazaki Hiroshi; Kamataki Tetsuya; Yoovathaworn Krongtong
In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.
Drug metabolism and pharmacokinetics 2006;21(6):475-84.
2006: Kamataki Tetsuya
[How I was enticed into molecular toxicology]
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2006;126(12):1309-18.
2006: Saruwatari Junji; Matsunaga Masayuki; Ikeda Kazuyuki; Nakao Masashi; Oniki Kentaro; Seo Takayuki; Mihara Shuichi; Marubayashi Toru; Kamataki Tetsuya; Nakagawa Kazuko
Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia.
European journal of clinical pharmacology 2006;62(12):995-1001.
2006: Sarikaya Devrim; Bilgen Cem; Kamataki Tetsuya; Topcu Zeki
Comparative cytochrome P450 -1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level.
Biopharmaceutics & drug disposition 2006;27(8):353-9.
2006: Uno Yasuhiro; Fujino Hideki; Kito Go; Kamataki Tetsuya; Nagata Ryoichi
CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone.
Molecular pharmacology 2006;70(2):477-86.
2006: Kuribayashi S; Ueda N; Naito S; Yamazaki H; Kamataki T
Species differences in hydrolase activities toward OT-7100 responsible for different bioavailability in rats, dogs, monkeys and humans.
Xenobiotica; the fate of foreign compounds in biological systems 2006;36(4):301-14.
2006: Takeuchi Hijiri; Saoo Kousuke; Matsuda Yoko; Yokohira Masanao; Yamakawa Keiko; Zeng Yu; Miyazaki Masafumi; Fujieda Masaki; Kamataki Tetsuya; Imaida Katsumi
Dose dependent inhibitory effects of dietary 8-methoxypsoralen on NNK-induced lung tumorigenesis in female A/J mice.
Cancer letters 2006;234(2):232-8.
2006: Iwano Shunsuke; Shibahara Norihito; Saito Tetsuya; Kamataki Tetsuya
Activation of p53 as a causal step for atherosclerosis induced by polycyclic aromatic hydrocarbons.
FEBS letters 2006;580(3):890-3.
2005: Kamataki Tetsuya; Fujieda Masaki; Kiyotani Kazuma; Iwano Shunsuke; Kunitoh Hideo
Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.
Biochemical and biophysical research communications 2005;338(1):306-10.
2005: Iwano Shunsuke; Asanuma Fumie; Nukaya Manabu; Saito Tetsuya; Kamataki Tetsuya
CYP1A1-mediated mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons.
Biochemical and biophysical research communications 2005;337(2):708-12.
2005: Miyazaki Masafumi; Yamazaki Hiroshi; Takeuchi Hijiri; Saoo Kousuke; Yokohira Masanao; Masumura Ken-ichi; Nohmi Takehiko; Funae Yoshihiko; Imaida Katsumi; Kamataki Tetsuya
Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas.
Carcinogenesis 2005;26(11):1947-55.
2005: Iwano Shunsuke; Nukaya Manabu; Saito Tetsuya; Asanuma Fumie; Kamataki Tetsuya
A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons.
Biochemical and biophysical research communications 2005;335(1):220-6.
2005: Kimura Miyuki; Yamazaki Hiroshi; Fujieda Masaki; Kiyotani Kazuma; Honda Goro; Saruwatari Junji; Nakagawa Kazuko; Ishizaki Takashi; Kamataki Tetsuya
Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(9):1361-6.
2005: Kamataki Tetsuya
[Tailor-made medicine]
Nippon yakurigaku zasshi. Folia pharmacologica Japonica 2005;126(1):60-5.
2005: Yamazaki Hiroshi; Fujieda Masaki; Cashman John R; Kamataki Tetsuya
Mild trimethylaminuria observed in a Japanese cohort with liver damage.
The American journal of medicine 2005;118(7):803-5.
2005: Nakamura Katsunori; Ariyoshi Noritaka; Iwatsubo Takafumi; Fukunaga Yasuhisa; Higuchi Saburou; Itoh Kunio; Shimada Noriaki; Nagashima Kazuo; Yokoi Tsuyoshi; Yamamoto Koujirou; Horiuchi Ryuya; Kamataki Tetsuya
Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.
Biological & pharmaceutical bulletin 2005;28(5):882-5.
2005: Endo Megumi; Takahashi Yoshiki; Sasaki Yasumasa; Saito Tetsuya; Kamataki Tetsuya
Novel gender-related regulation of CYP2C12 gene expression in rats.
Molecular endocrinology (Baltimore, Md.) 2005;19(5):1181-90.
2005: Miyazaki Masafumi; Sugawara Eika; Yoshimura Teruki; Yamazaki Hiroshi; Kamataki Tetsuya
Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108.
Mutation research 2005;581(1-2):165-71.
2005: Gyamfi Maxwell Afari; Fujieda Masaki; Kiyotani Kazuma; Yamazaki Hiroshi; Kamataki Tetsuya
High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.
European journal of clinical pharmacology 2005;60(12):855-7.
2005: Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Saito T; Parkinson A; Nakagawa K; Kamataki T
Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.
Xenobiotica; the fate of foreign compounds in biological systems 2005;35(1):69-83.
2004: Nishimura Masuhiro; Imai Teruko; Morioka Yujiro; Kuribayashi Shunji; Kamataki Tetsuya; Naito Shinsaku
Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes.
Drug metabolism and pharmacokinetics 2004;19(6):422-9.
2004: Fujieda Masaki; Yamazaki Hiroshi; Saito Tetsuya; Kiyotani Kazuma; Gyamfi Maxwell Afari; Sakurai Masaharu; Dosaka-Akita Hirotoshi; Sawamura Yuichi; Yokota Jun; Kunitoh Hideo; Kamataki Tetsuya
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Carcinogenesis 2004;25(12):2451-8.
2004: Ariyoshi Noritaka; Sekine Hiromi; Nakayama Kazuo; Saito Katsuhiko; Miyamoto Atsushi; Kamataki Tetsuya
Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese.
Pharmacogenetics 2004;14(10):701-5.
2004: Yamazaki Yoshiyuki; Fujita Ken-Ichi; Nakayama Kazuo; Suzuki Akihiro; Nakamura Katsunori; Yamazaki Hiroshi; Kamataki Tetsuya
Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens.
Mutation research 2004;562(1-2):151-62.
2004: Furukawa Motonobu; Nishimura Masuhiro; Ogino Daisuke; Chiba Ryoji; Ikai Iwao; Ueda Nobuhiko; Naito Shinsaku; Kuribayashi Shunji; Moustafa Mohsen A; Uchida Takafumi; Sawada Hideki; Kamataki Tetsuya; Funae Yoshihiko; Fukumoto Manabu
Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver.
Cancer science 2004;95(6):520-9.
2004: Yamaori Satoshi; Yamazaki Hiroshi; Iwano Shunsuke; Kiyotani Kazuma; Matsumura Keiko; Honda Goro; Nakagawa Kazuko; Ishizaki Takashi; Kamataki Tetsuya
CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Drug metabolism and pharmacokinetics 2004;19(2):120-9.
2004: Yamazaki Hiroshi; Fujieda Masaki; Togashi Masahiro; Saito Tetsuya; Preti George; Cashman John R; Kamataki Tetsuya
Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients.
Life sciences 2004;74(22):2739-47.
2004: Sakuma Tsutomu; Shimojima Tsukasa; Miwa Kiyoshi; Kamataki Tetsuya
Cloning CYP2D21 and CYP3A22 cDNAs from liver of miniature pigs.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(4):376-8.
2004: Toide Kenji; Terauchi Yoshiaki; Fujii Toshihiko; Yamazaki Hiroshi; Kamataki Tetsuya
Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes.
Biochemical pharmacology 2004;67(7):1269-78.
2004: Matsumura Keiko; Saito Tetsuya; Takahashi Yoshiki; Ozeki Takeshi; Kiyotani Kazuma; Fujieda Masaki; Yamazaki Hiroshi; Kunitoh Hideo; Kamataki Tetsuya
Identification of a novel polymorphic enhancer of the human CYP3A4 gene.
Molecular pharmacology 2004;65(2):326-34.
2004: Nukaya Manabu; Takahashi Yoshiki; Gonzalez Frank J; Kamataki Tetsuya
Aryl hydrocarbon receptor-mediated suppression of GH receptor and Janus kinase 2 expression in mice.
FEBS letters 2004;558(1-3):96-100.
2003: Yamaori Satoshi; Yamazaki Hiroshi; Suzuki Akihiro; Yamada Ayako; Tani Hirofumi; Kamidate Tamio; Fujita Ken ichi; Kamataki Tetsuya
Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
Biochemical pharmacology 2003;66(12):2333-40.
2003: Takeuchi Hijiri; Saoo Kousuke; Yokohira Masanao; Ikeda Mico; Maeta Hajime; Miyazaki Masafumi; Yamazaki Hiroshi; Kamataki Tetsuya; Imaida Katsumi
Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.
Cancer research 2003;63(22):7581-3.
2003: Kiyotani Kazuma; Yamazaki Hiroshi; Fujieda Masaki; Iwano Shunsuke; Matsumura Keiko; Satarug Soisungwan; Ujjin Pailin; Shimada Tsutomu; Guengerich F Peter; Parkinson Andrew; Honda Goro; Nakagawa Kazuko; Ishizaki Takashi; Kamataki Tetsuya
Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).
Pharmacogenetics 2003;13(11):689-95.
2003: Mizuno Dai; Takahashi Yoshiki; Hiroi Toyoko; Imaoka Susumu; Kamataki Tetsuya; Funae Yoshihiko
A novel transcriptional element which regulates expression of the CYP2D4 gene by Oct-1 and YY-1 binding.
Biochimica et biophysica acta 2003;1627(2-3):121-8.
2003: Ando Masahiko; Hamajima Nobuyuki; Ariyoshi Noritaka; Kamataki Tetsuya; Matsuo Keitaro; Ohno Yoshiyuki
Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults.
Journal of epidemiology / Japan Epidemiological Association 2003;13(3):176-81.
2003: Satoh Takashi; Munakata Haruka; Fujita Ken-ichi; Itoh Shinji; Itoh Shungo; Kamataki Tetsuya; Yoshizawa Itsuo
Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17.
Biological & pharmaceutical bulletin 2003;26(5):695-700.
2003: Toide Kenji; Yamazaki Hiroshi; Nagashima Rikako; Itoh Keisuke; Iwano Shunsuke; Takahashi Yoshiki; Watanabe Shaw; Kamataki Tetsuya
Aryl hydrocarbon hydroxylase represents CYP1B1, and not CYP1A1, in human freshly isolated white cells: trimodal distribution of Japanese population according to induction of CYP1B1 mRNA by environmental dioxins.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2003;12(3):219-22.
2003: Ozeki Takeshi; Takahashi Yoshiki; Nakayama Kazuo; Funayama Masato; Nagashima Kazuo; Kodama Takao; Kamataki Tetsuya
Hepatocyte nuclear factor-4 alpha/gamma and hepatocyte nuclear factor-1 alpha as causal factors of interindividual difference in the expression of human dihydrodiol dehydrogenase 4 mRNA in human livers.
Pharmacogenetics 2003;13(1):49-53.
2003: Fujieda Masaki; Yamazaki Hiroshi; Togashi Masahiro; Saito Tetsuya; Kamataki Tetsuya
Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese.
Drug metabolism and pharmacokinetics 2003;18(5):333-5.
2003: Yamazaki Hiroshi; Kiyotani Kazuma; Tsubuko Satoshi; Matsunaga Masayuki; Fujieda Masaki; Saito Tetsuya; Miura Jun; Kobayashi Shinichi; Kamataki Tetsuya
Two novel haplotypes of CYP2D6 gene in a Japanese population.
Drug metabolism and pharmacokinetics 2003;18(4):269-71.
2003: Saito Tetsuya; Egashira Mari; Kiyotani Kazuma; Fujieda Masaki; Yamazaki Hiroshi; Kiyohara Chikako; Kunitoh Hideo; Kamataki Tetsuya
Novel nonsynonymous polymorphisms of the CYP1A1 gene in Japanese.
Drug metabolism and pharmacokinetics 2003;18(3):218-21.
2003: Ng Poh-Sing; Imaoka Susumu; Hiroi Toyoko; Osada Mayuko; Niwa Toshio; Kamataki Tetsuya; Funae Yoshihiko
Production of inhibitory polyclonal antibodies against cytochrome P450s.
Drug metabolism and pharmacokinetics 2003;18(3):163-72.
2003: Fujieda Masaki; Yamazaki Hiroshi; Kiyotani Kazuma; Muroi Asami; Kunitoh Hideo; Dosaka-Akita Hirotoshi; Sawamura Yuichi; Kamataki Tetsuya
Eighteen novel polymorphisms of the CYP2A13 gene in Japanese.
Drug metabolism and pharmacokinetics 2003;18(1):86-90.
2003: Kanamori Yoichi; Fujita Ken-Ichi; Nakayama Kazuo; Kawai Hideki; Kamataki Tetsuya
Large-scale production of genetically engineered CYP3A4 in E. coli: application of a jarfermenter.
Drug metabolism and pharmacokinetics 2003;18(1):42-7.
2002: Chida Michihiro; Ariyoshi Noritaka; Yokoi Tsuyoshi; Nemoto Nobuo; Inaba Makoto; Kinoshita Moritoshi; Kamataki Tetsuya
New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine.
Pharmacogenetics 2002;12(8):659-62.
2002: Takahashi Eizo; Fujita Ken-ichi; Kamataki Tetsuya; Arimoto-Kobayashi Sakae; Okamoto Keinosuke; Negishi Tomoe
Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin.
Mutation research 2002;508(1-2):147-56.
2002: Ariyoshi Noritaka; Miyamoto Masami; Umetsu Yuri; Kunitoh Hideo; Dosaka-Akita Hirotoshi; Sawamura Yu-Ichi; Yokota Jun; Nemoto Nobuo; Sato Kunio; Kamataki Tetsuya
Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002;11(9):890-4.
2002: Ozeki Takeshi; Takahashi Yoshiki; Nakayama Kazuo; Kamataki Tetsuya
Hepatocyte nuclear factor (HNF)-4 alpha/gamma, HNF-1 alpha, and vHNF-1 regulate the cell-specific expression of the human dihydrodiol dehydrogenase (DD)4/AKR1C4 gene.
Archives of biochemistry and biophysics 2002;405(2):185-90.
2002: Kamataki Tetsuya; Fujita Ken-ichi; Nakayama Kazuo; Yamazaki Yoshiyuki; Miyamoto Masami; Ariyoshi Noritaka
Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
Drug metabolism reviews 2002;34(3):667-76.
2002: Saruwatari Junji; Nakagawa Kazuko; Shindo Junichi; Tajiri Takahiro; Fujieda Masaki; Yamazaki Hiroshi; Kamataki Tetsuya; Ishizaki Takashi
A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test.
Clinical pharmacology and therapeutics 2002;72(2):200-8.
2002: Ariyoshi Noritaka; Sekine Hiromi; Saito Katsuhiko; Kamataki Tetsuya
Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese.
Pharmacogenetics 2002;12(6):501-4.
2002: Daigo Satoshi; Takahashi Yoshiki; Fujieda Masaki; Ariyoshi Noritaka; Yamazaki Hiroshi; Koizumi Wasaburo; Tanabe Satoshi; Saigenji Katsunori; Nagayama Sekio; Ikeda Kazumasa; Nishioka Yasuhiko; Kamataki Tetsuya
A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Pharmacogenetics 2002;12(4):299-306.
2002: Toide Kenji; Takahashi Yoshiki; Yamazaki Hiroshi; Terauchi Yoshiaki; Fujii Toshihiko; Parkinson Andrew; Kamataki Tetsuya
Hepatocyte nuclear factor-1alpha is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):613-5.
2002: Ariyoshi Noritaka; Kitada Mitsukazu; Kamataki Tetsuya
[Association between genetic polymorphism and lung cancer risk]
Nippon rinsho. Japanese journal of clinical medicine 2002;60 Suppl 5():46-9.
2002: Nakamura Katsunori; Ariyoshi Noritaka; Yokoi Tsuyoshi; Ohgiya Satoru; Chida Michihiro; Nagashima Kazuo; Inoue Kazuaki; Kodama Takao; Shimada Noriaki; Kamataki Tetsuya
CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Biochemical and biophysical research communications 2002;293(3):969-73.
2002: Fujieda Masaki; Yamazaki Hiroshi; Kamataki Tetsuya
[Genetic polymorphisms of drug metabolizing enzymes]
Gan to kagaku ryoho. Cancer & chemotherapy 2002;29(5):663-8.
2002: Yamazaki Hiroshi; Kamataki Tetsuya
[P450 and carcinogenesis]
Nippon yakurigaku zasshi. Folia pharmacologica Japonica 2002;119(4):208-12.
2002: Topcu Zeki; Chiba Itsuo; Fujieda Masaki; Shibata Toshiyuki; Ariyoshi Noritaka; Yamazaki Hiroshi; Sevgican Figen; Muthumala Malsantha; Kobayashi Hiroshi; Kamataki Tetsuya
CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka.
Carcinogenesis 2002;23(4):595-8.
2002: Ujjin Pailin; Satarug Soisungwan; Vanavanitkun Yuvaree; Daigo Satoshi; Ariyoshi Noritaka; Yamazaki Hiroshi; Reilly Paul E B; Moore Michael R; Kamataki Tetsuya
Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females.
Pharmacogenetics 2002;12(3):241-9.
2002: Hashizume Takanori; Imaoka Susumu; Mise Masashi; Terauchi Yoshiaki; Fujii Toshihiko; Miyazaki Hisashi; Kamataki Tetsuya; Funae Yoshihiko
Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.
The Journal of pharmacology and experimental therapeutics 2002;300(1):298-304.
2002: Kiyotani Kazuma; Fujieda Masaki; Yamazaki Hiroshi; Shimada Tsutomu; Guengerich F Peter; Parkinson Andrew; Nakagawa Kazuko; Ishizaki Takashi; Kamataki Tetsuya
Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians.
Drug metabolism and pharmacokinetics 2002;17(5):482-7.
2002: Kubota Megumi; Nakamoto Yoko; Nakayama Kazuo; Ujjin Pailin; Satarug Soisungwan; Mushiroda Taisei; Yokoi Tsuyoshi; Funayama Masato; Kamataki Tetsuya
A mutation in the flavin-containing monooxygenase 3 gene and its effects on catalytic activity for N-oxidation of trimethylamine in vitro.
Drug metabolism and pharmacokinetics 2002;17(3):207-13.
2002: Toide Kenji; Umeda Shin-Ichiro; Yamazaki Hiroshi; Takahashi Yoshiki; Terauchi Yoshiaki; Fujii Toshihiko; Kamataki Tetsuya
A major genotype in UDP-glucuronosyltransferase 2B15.
Drug metabolism and pharmacokinetics 2002;17(2):164-6.
2002: Kiyotani Kazuma; Yamazaki Hiroshi; Fujieda Masaki; Daigo Satoshi; Satarug Soisungwan; Ujjin Pailin; Kamataki Tetsuya
Novel mutations of the CYP2A6 gene in a Thai population with lowered capacity of coumarin 7-hydroxylation.
Drug metabolism and pharmacokinetics 2002;17(2):161-3.
2002: Fujita Ken-Ichi; Kamataki Tetsuya
Genetically engineered bacterial cells co-expressing human cytochrome P450 with NADPH-cytochrome P450 reductase: prediction of metabolism and toxicity of drugs in humans.
Drug metabolism and pharmacokinetics 2002;17(1):1-22.
2002: Kamataki Tetsuya; Fujita Ken-Ichi
Mutagenesis testing based on bacterial expression of human P450s.
Methods in enzymology 2002;357():301-10.
2001: Fujita K; Kamataki T
Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
Mutation research 2001;483(1-2):35-41.
2001: Nakayama K; Sudo Y; Sasaki Y; Iwata H; Takahashi M; Kamataki T
Studies on transcriptional regulation of Cyp3a16 gene in mouse livers by application of direct DNA injection method.
Biochemical and biophysical research communications 2001;287(4):820-4.
2001: Saito T; Takahashi Y; Hashimoto H; Kamataki T
Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor kappa B-like element.
The Journal of biological chemistry 2001;276(41):38010-22.
2001: Baker J R; Satarug S; Reilly P E; Edwards R J; Ariyoshi N; Kamataki T; Moore M R; Williams D J
Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples.
Biochemical pharmacology 2001;62(6):713-21.
2001: Nukaya M; Takahashi Y; Gonzalez F J; Kamataki T
Aryl hydrocarbon receptor-mediated suppression of expression of the low-molecular-weight prekininogen gene in mice.
Biochemical and biophysical research communications 2001;287(1):301-4.
2001: Iwano S; Saito T; Takahashi Y; Fujita K; Kamataki T
Cooperative regulation of CYP3A5 gene transcription by NF-Y and Sp family members.
Biochemical and biophysical research communications 2001;286(1):55-60.
2001: Muto S; Fujita K; Yamazaki Y; Kamataki T
Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450.
Mutation research 2001;479(1-2):197-206.
2001: Fujita K; Kamataki T
Screening of organosulfur compounds as inhibitors of human CYP2A6.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(7):983-9.
2001: Imaoka S; Hayashi K; Hiroi T; Yabusaki Y; Kamataki T; Funae Y
A transgenic mouse expressing human CYP4B1 in the liver.
Biochemical and biophysical research communications 2001;284(3):757-62.
2001: Hashizume T; Mise M; Matsumoto S; Terauchi Y; Fujii T; Imaoka S; Funae Y; Kamataki T; Miyazaki H
A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(6):798-805.
2001: Ozeki T; Takahashi Y; Kume T; Nakayama K; Yokoi T; Nunoya K; Hara A; Kamataki T
Co-operative regulation of the transcription of human dihydrodiol dehydrogenase (DD)4/aldo-keto reductase (AKR)1C4 gene by hepatocyte nuclear factor (HNF)-4alpha/gamma and HNF-1alpha.
The Biochemical journal 2001;355(Pt 2):537-44.
2001: Ariyoshi N; Miyazaki M; Toide K; Sawamura Yi; Kamataki T
A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation.
Biochemical and biophysical research communications 2001;281(5):1256-60.
2001: Ariyoshi N; Sawamura Y; Kamataki T
A novel single nucleotide polymorphism altering stability and activity of CYP2a6.
Biochemical and biophysical research communications 2001;281(3):810-4.
2001: Takahashi Y; Kamataki T
Competitive inhibition of the transcription of rabbit CYP1A1 gene by upstream stimulatory factor 1 (USF1).
Drug metabolism reviews 2001;33(1):37-47.
2001: Mushiroda T; Ariyoshi N; Yokoi T; Takahara E; Nagata O; Kato H; Kamataki T
Accumulation of the 1-methyl-4-phenylpyridinium ion in suncus (Suncus murinus) brain: implication for flavin-containing monooxygenase activity in brain microvessels.
Chemical research in toxicology 2001;14(2):228-32.
2001: Loriot M A; Rebuissou S; Oscarson M; Cenée S; Miyamoto M; Ariyoshi N; Kamataki T; Hémon D; Beaune P; Stücker I
Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population.
Pharmacogenetics 2001;11(1):39-44.
2001: Hashizume T; Imaoka S; Hiroi T; Terauchi Y; Fujii T; Miyazaki H; Kamataki T; Funae Y
cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine.
Biochemical and biophysical research communications 2001;280(4):1135-41.
2001: Fujita K; Kamataki T
Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase.
Environmental and molecular mutagenesis 2001;38(4):339-46.
2001: Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Environmental and molecular mutagenesis 2001;38(4):329-38.
2000: Ariyoshi N; Takahashi Y; Miyamoto M; Umetsu Y; Daigo S; Tateishi T; Kobayashi S; Mizorogi Y; Loriot M A; Stücker I; Beaune P; Kinoshita M; Kamataki T
Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.
Pharmacogenetics 2000;10(8):687-93.
2000: Kushida H; Fujita K; Suzuki A; Yamada M; Nohmi T; Kamataki T
Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108.
Mutation research 2000;471(1-2):135-43.
2000: Satoh T; Fujita K I; Munakata H; Itoh S; Nakamura K; Kamataki T; Itoh S; Yoshizawa I
Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase.
Analytical biochemistry 2000;286(2):179-86.
2000: Mushiroda T; Yokoi T; Itoh K; Nunoya K; Nakagawa T; Kubota M; Takahara E; Nagata O; Kato H; Kamataki T
The house musk shrew (Suncus murinus): a unique animal with extremely low level of expression of mRNAs for CYP3A and flavin-containing monooxygenase.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 2000;126(3):225-34.
2000: Kushida H; Fujita K; Suzuki A; Yamada M; Endo T; Nohmi T; Kamataki T
Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase.
Carcinogenesis 2000;21(6):1227-32.
2000: Inoue E; Takahashi Y; Imai Y; Kamataki T
Development of bacterial expression system with high yield of CYP3A7, a human fetus-specific form of cytochrome P450.
Biochemical and biophysical research communications 2000;269(2):623-7.
2000: Mushiroda T; Ariyoshi N; Kimura K; Takahara E; Nagata O; Kato H; Kamataki T
A high-level expression of CYP2A in the lung of the suncus (Suncus murinus) and its role in the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Biochemical and biophysical research communications 2000;269(2):393-6.
2000: Mushiroda T; Yokoi T; Takahara E; Nagata O; Kato H; Kamataki T
The suncus (Suncus murinus) shows poor metabolic phenotype for trimethylamine N-oxygenation.
Toxicology and applied pharmacology 2000;162(1):44-8.
1999: Kume T; Iwasa H; Shiraishi H; Yokoi T; Nagashima K; Otsuka M; Terada T; Takagi T; Hara A; Kamataki T
Characterization of a novel variant (S145C/L311V) of 3alpha-hydroxysteroid/dihydrodiol dehydrogenase in human liver.
Pharmacogenetics 1999;9(6):763-71.
1999: Sasaki Y; Takahashi Y; Nakayama K; Kamataki T
Cooperative regulation of CYP2C12 gene expression by STAT5 and liver-specific factors in female rats.
The Journal of biological chemistry 1999;274(52):37117-24.
1999: Mushiroda T; Yokoi T; Takahara E; Nagata O; Kato H; Kamataki T
Sensitive assay of trimethylamine N-oxide in liver microsomes by headspace gas chromatography with flame thermionic detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;734(2):319-23.
1999: Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez F J; Kamataki T
Genetic polymorphism of CYP2D6 in the Japanese population.
Pharmacogenetics 1999;9(5):601-5.
1999: Chida M; Yokoi T; Fukui T; Kinoshita M; Yokota J; Kamataki T
Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population.
Japanese journal of cancer research : Gann 1999;90(9):899-902.
1999: Kamataki T; Suzuki A; Kushida H; Iwata H; Watanabe M; Nohmi T; Fujita K
Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocylic amines.
Cancer letters 1999;143(2):113-6.
1999: Kashiyama E; Yokoi T; Odomi M; Kamataki T
Stereoselective S-oxidation and reduction of flosequinan in rat.
Xenobiotica; the fate of foreign compounds in biological systems 1999;29(8):815-26.
1999: Marczylo T H; Hayatsu T; Arimoto-Kobayashi S; Tada M; Fujita K; Kamataki T; Nakayama K; Hayatsu H
Protection against the bacterial mutagenicity of heterocyclic amines by purpurin, a natural anthraquinone pigment.
Mutation research 1999;444(2):451-61.
1999: Miyamoto M; Umetsu Y; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Nemoto N; Sato K; Ariyoshi N; Kamataki T
CYP2A6 gene deletion reduces susceptibility to lung cancer.
Biochemical and biophysical research communications 1999;261(3):658-60.
1999: Nunoya K; Yokoi T; Takahashi Y; Kimura K; Kinoshita M; Kamataki T
Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype.
Journal of biochemistry 1999;126(2):402-7.
1999: Chida M; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T
A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype.
Pharmacogenetics 1999;9(3):287-93.
1999: Tateishi T; Chida M; Ariyoshi N; Mizorogi Y; Kamataki T; Kobayashi S
Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population.
Clinical pharmacology and therapeutics 1999;65(5):570-5.
1999: Nakajima M; Yokoi T; Mizutani M; Kinoshita M; Funayama M; Kamataki T
Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.
Journal of biochemistry 1999;125(4):803-8.
1999: Nunoya K I; Yokoi T; Kimura K; Kainuma T; Satoh K; Kinoshita M; Kamataki T
A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans.
The Journal of pharmacology and experimental therapeutics 1999;289(1):437-42.
1999: Muto S; Yokoi T; Gondo Y; Katsuki M; Shioyama Y; Fujita K; Kamataki T
Inhibition of benzo[a]pyrene-induced mutagenesis by (-)-epigallocatechin gallate in the lung of rpsL transgenic mice.
Carcinogenesis 1999;20(3):421-4.
1998: Ando Y; Shimizu T; Nakamura K; Mushiroda T; Nakagawa T; Kodama T; Kamataki T
Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.
British journal of cancer 1998;78(9):1170-4.
1998: Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(8):845-7.
1998: Ando Y; Chida M; Nakayama K; Saka H; Kamataki T
The UGT1A1*28 allele is relatively rare in a Japanese population.
Pharmacogenetics 1998;8(4):357-60.
1998: Yokoi T; Kamataki T
[Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese]
Nippon yakurigaku zasshi. Folia pharmacologica Japonica 1998;112(1):5-14.
1998: Sakuma T; Hieda M; Igarashi T; Ohgiya S; Nagata R; Nemoto N; Kamataki T
Molecular cloning and functional analysis of cynomolgus monkey CYP1A2.
Biochemical pharmacology 1998;56(1):131-9.
1998: Nunoya K; Yokoi T; Kimura K; Inoue K; Kodama T; Funayama M; Nagashima K; Funae Y; Green C; Kinoshita M; Kamataki T
A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).
Pharmacogenetics 1998;8(3):239-49.
1998: Takahashi Y; Suzuki C; Kamataki T
Silencing of CYP1A1 expression in rabbits by DNA methylation.
Biochemical and biophysical research communications 1998;247(2):383-6.
1998: Mori T; Itoh S; Kamataki T
Molecular cloning and regulation of a novel guinea pig cytochrome P450 (CYP3A20) which differs from guinea pig CYP3A14 in only two amino acid residues.
Biochemistry and molecular biology international 1998;44(6):1245-53.
1998: Suzuki A; Kushida H; Iwata H; Watanabe M; Nohmi T; Fujita K; Gonzalez F J; Kamataki T
Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocyclic amines.
Cancer research 1998;58(9):1833-8.
1998: Iwata H; Fujita K; Kushida H; Suzuki A; Konno Y; Nakamura K; Fujino A; Kamataki T
High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli.
Biochemical pharmacology 1998;55(8):1315-25.
1998: Yokoi T; Kamataki T
Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
Pharmaceutical research 1998;15(4):517-24.
1997: Mori T; Itoh S; Ohgiya S; Ishizaki K; Kamataki T
Regulation of CYP1A and CYP3A mRNAs by ascorbic acid in guinea pigs.
Archives of biochemistry and biophysics 1997;348(2):268-77.
1997: Takahashi Y; Nakayama K; Itoh S; Kamataki T
Upstream stimulatory factor 1 (USF1) suppresses induction of CYP1A1 mRNA by 3-methylcholanthrene (MC) in HepG2 cells.
Biochemical and biophysical research communications 1997;240(2):293-7.
1997: Takahashi Y; Nakayama K; Itoh S; Fujii-Kuriyama Y; Kamataki T
Inhibition of the transcription of CYP1A1 gene by the upstream stimulatory factor 1 in rabbits. Competitive binding of USF1 with AhR.Arnt complex.
The Journal of biological chemistry 1997;272(48):30025-31.
1997: Sakuma T; Igarashi T; Hieda M; Ohgiya S; Isogai M; Ninomiya S; Nagata R; Nemoto N; Kamataki T
Marmoset CYP1A2: primary structure and constitutive expression in livers.
Carcinogenesis 1997;18(10):1985-91.
1997: Gillam E M; Wunsch R M; Ueng Y F; Shimada T; Reilly P E; Kamataki T; Guengerich F P
Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5' modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase.
Archives of biochemistry and biophysics 1997;346(1):81-90.
1997: Kubo A; Itoh S; Itoh K; Kamataki T
Determination of FAD-binding domain in flavin-containing monooxygenase 1 (FMO1).
Archives of biochemistry and biophysics 1997;345(2):271-7.
1997: Ohgiya S; Goda T; Hoshino T; Kamataki T; Ishizaki K
Establishment of a novel host, high-red yeast that stably expresses hamster NADPH-cytochrome P450 oxidoreductase: usefulness for examination of the function of mammalian cytochrome P450.
Archives of biochemistry and biophysics 1997;343(2):215-24.
1997: Kashiyama E; Yokoi T; Odomi M; Funae Y; Inoue K; Kamataki T
Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(6):716-24.
1997: Itoh S; Matsuyama T; Kamataki T
Low activity of aldehyde dehydrogenase (ALDH) in liver of Suncus murinus: possible explanation for high sensitivity to alcohol.
The Journal of toxicological sciences 1997;22(2):111-5.
1997: Yanagimoto T; Itoh S; Sawada M; Kamataki T
Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1.
Archives of biochemistry and biophysics 1997;340(2):215-8.
1997: Igarashi T; Sakuma T; Isogai M; Nagata R; Kamataki T
Marmoset liver cytochrome P450s: study for expression and molecular cloning of their cDNAs.
Archives of biochemistry and biophysics 1997;339(1):85-91.
1997: Itoh K; Nakamura K; Kimura T; Itoh S; Kamataki T
Molecular cloning of mouse liver flavin containing monooxygenase (FMO1) cDNA and characterization of the expression product: metabolism of the neurotoxin, 1,2,3,4-tetrahydroisoquinoline (TIQ).
The Journal of toxicological sciences 1997;22(1):45-56.
1997: Nakura H; Itoh S; Kusano H; Ishizone H; Kamataki T
Opposite effects of isoniazid and fasting on the expression of CYP2E1 protein and mRNA in house musk shrew (Suncus murinus).
Biochemistry and molecular biology international 1997;41(2):293-301.
1997: Itoh S; Abe Y; Kubo A; Okuda M; Shimoji M; Nakayama K; Kamataki T
Isolation of a promoter region in mouse cytochrome P450 3A (Cyp3A16) gene and its transcriptional control.
Biochimica et biophysica acta 1997;1350(2):155-8.
1997: Li Y; Yokoi T; Katsuki M; Wang J S; Groopman J D; Kamataki T
In vivo activation of aflatoxin B1 in C57BL/6N mice carrying a human fetus-specific CYP3A7 gene.
Cancer research 1997;57(4):641-5.
1997: Toide K; Itoh S; Nagasaka Y; Yanagimoto T; Kamataki T
Gene structure of mouse Cyp3a11: evidence for an enhancer element within its 5' flanking sequences.
Archives of biochemistry and biophysics 1997;338(1):43-9.
1996: Kamataki T; Yokoi T; Yamayoshi Y; Nakamura K; Kushida H; Fujita K; Mitsuhashi H; Ueno T
Strategic proposals to avoid toxic drug interactions during new drug development: molecular toxicology proposals.
The Journal of toxicological sciences 1996;21(5):305-8.
1996: Takahashi Y; Nakayama K; Shimojima T; Itoh S; Kamataki T
Expression of aryl hydrocarbon receptor (AhR) and aryl hydrocarbon receptor nuclear translocator (Arnt) in adult rabbits known to be non-responsive to cytochrome P-450 1A1 (CYP1A1) inducers.
European journal of biochemistry / FEBS 1996;242(3):512-8.
1996: Li Y; Yokoi T; Sasaki M; Hattori K; Katsuki M; Kamataki T
Perinatal expression and inducibility of human CYP3A7 in C57BL/6N transgenic mice.
Biochemical and biophysical research communications 1996;228(2):312-7.
1996: Nakamura K; Yokoi T; Inoue K; Shimada N; Ohashi N; Kume T; Kamataki T
CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.
Pharmacogenetics 1996;6(5):449-57.
1996: Yokoi T; Kosaka Y; Chida M; Chiba K; Nakamura H; Ishizaki T; Kinoshita M; Sato K; Gonzalez F J; Kamataki T
A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.
Pharmacogenetics 1996;6(5):395-401.
1996: Nakagawa T; Sawada M; Gonzalez F J; Yokoi T; Kamataki T
Stable expression of human CYP2E1 in Chinese hamster cells: high sensitivity to N,N-dimethylnitrosamine in cytotoxicity testing.
Mutation research 1996;360(3):181-6.
1996: Shimoji M; Itoh S; Toide K; Nakayama K; Aizawa S; Kamataki T
Application of primary hepatocytes from p53-knockout mice for studies of expression of Cyp3a.
Journal of biochemistry 1996;120(1):42-8.
1996: Li Y; Yokoi T; Kitamura R; Sasaki M; Gunji M; Katsuki M; Kamataki T
Establishment of transgenic mice carrying human fetus-specific CYP3A7.
Archives of biochemistry and biophysics 1996;329(2):235-240.
1996: Nunoya K; Yokoi Y; Kimura K; Kodama T; Funayama M; Inoue K; Nagashima K; Funae Y; Shimada N; Green C; Kamataki T
(+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes.
The Journal of pharmacology and experimental therapeutics 1996;277(2):768-74.
1995: Nunoya K; Yokoi T; Itoh K; Itoh S; Kimura K; Kamataki T
S-oxidation of (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidin-4-one hydrochloride by rat hepatic flavin-containing monooxygenase 1 expressed in yeast.
Xenobiotica; the fate of foreign compounds in biological systems 1995;25(12):1283-91.
1995: Kamataki T; Hashimoto H; Shimoji M; Itoh S; Nakayama K; Hattori K; Yokoi T; Katsuki M; Aizawa S
Expression of CYP3A7, a human fetus-specific cytochrome P450, in cultured cells and in the hepatocytes of p53-knockout mice.
Toxicology letters 1995;82-83():879-82.
1995: Shimoji M; Hattori K; Itoh S; Nakayama K; Katsuki M; Aizawa S; Yokoi T; Kamataki T
Establishment of immortal hepatocytes from a CYP3A7-transgenic/p53-knockout mouse.
Biochemical and biophysical research communications 1995;217(3):1001-5.
1995: Yokoi T; Narita M; Nagai E; Hagiwara H; Aburada M; Kamataki T
Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate.
Japanese journal of cancer research : Gann 1995;86(10):985-9.
1995: Nakura H; Itoh S; Kusano H; Ishizone H; Deguchi T; Kamataki T
Evidence for the lack of hepatic N-acetyltransferase in suncus (Suncus murinus).
Biochemical pharmacology 1995;50(8):1165-70.
1995: Hashimoto H; Yanagawa Y; Sawada M; Itoh S; Deguchi T; Kamataki T
Simultaneous expression of human CYP3A7 and N-acetyltransferase in Chinese hamster CHL cells results in high cytotoxicity for carcinogenic heterocyclic amines.
Archives of biochemistry and biophysics 1995;320(2):323-9.
1995: Sakuma T; Yokoi T; Kamataki T
Hormonal regulation of the mRNA level of male-dominant cytochrome P450 (CYP2C27) in hamster livers.
Pharmacological research : the official journal of the Italian Pharmacological Society 1995;31(6):371-4.
1995: Sakuma T; Yokoi T; Kamataki T
Isolation and characterization of a new cDNA clone belonging to the cytochrome P450 2C gene subfamily in hamsters.
Archives of biochemistry and biophysics 1995;319(1):267-73.
1995: Kamataki T
[Molecular toxicology of cytochrome P450: focusing on interspecies homology]
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 1995;115(5):370-7.
1995: Hashimoto H; Nakagawa T; Yokoi T; Sawada M; Itoh S; Kamataki T
Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins.
Cancer research 1995;55(4):787-91.
1995: Yokoi T; Nagayama S; Kajiwara R; Kawaguchi Y; Aizawa T; Otaki Y; Aburada M; Kamataki T
Occurrence of autoimmune antibodies to liver microsomal proteins associated with lethal hepatitis in LEC rats: effects of TJN-101 ((+)-(6S,7S,R-biar)- 5,6,7,8-tetrahydro-1,2,3,12-tetramethoxy-6,7-dimethyl-10,11- methylenedioxy-6-dibenzo[a,c]cyclooctenol) on the development of hepatitis and the autoantibodies.
Toxicology letters 1995;76(1):33-8.
1995: Sakuma T; Kitamura R; Yokoi T; Kamataki T
Efficient complementary DNA directed expression of human fetal liver cytochrome P450 (CYP3A7) in insect cells using baculovirus.
Biochemistry and molecular biology international 1995;35(2):447-55.
1995: Yokoi T; Sawada M; Kamataki T
Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations.
Pharmacogenetics 1995;5 Spec No():S65-9.
1994: Itoh S; Satoh M; Abe Y; Hashimoto H; Yanagimoto T; Kamataki T
A novel form of mouse cytochrome P450 3A (Cyp3a-16). Its cDNA cloning and expression in fetal liver.
European journal of biochemistry / FEBS 1994;226(3):877-82.
1994: Yanagimoto T; Itoh S; Sawada M; Hashimoto H; Kamataki T
Molecular cloning and functional expression of a mouse cytochrome P-450 (Cyp3a-13): examination of Cyp3a-13 enzyme to activate aflatoxin B1 (AFB1).
Biochimica et biophysica acta 1994;1201(3):405-10.
1994: Kato T; Nakasa H; Ohmori S; Kamataki T; Itahashi K; Shimada T; Rikihisa T; Kitada M
Possible occurrence of P450 related to P450 HFLb in extrahepatic tissues of human fetuses and its contribution to metabolic activation of promutagens.
Mutation research 1994;310(1):73-7.
1994: Takahashi Y; Itoh S; Shimojima T; Kamataki T
Characterization of Ah receptor promoter in human liver cell line, HepG2.
Pharmacogenetics 1994;4(4):219-22.
1994: Nagayama S; Yokoi T; Tanaka H; Kawaguchi Y; Shirasaka T; Kamataki T
Occurrence of autoantibody to protein disulfide isomerase in patients with hepatic disorder.
The Journal of toxicological sciences 1994;19(3):163-9.
1994: Nagayama S; Yokoi T; Kawaguchi Y; Kamataki T
Occurrence of autoantibody to protein disulfide isomerase in rats with xenobiotic-induced hepatitis.
The Journal of toxicological sciences 1994;19(3):155-61.
1994: Kashiyama E; Yokoi T; Todaka T; Odomi M; Kamataki T
Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan.
Biochemical pharmacology 1994;48(2):237-43.
1994: Yanagawa Y; Sawada M; Deguchi T; Gonzalez F J; Kamataki T
Stable expression of human CYP1A2 and N-acetyltransferases in Chinese hamster CHL cells: mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline.
Cancer research 1994;54(13):3422-7.
1994: Yokoi T; Nagayama S; Kajiwara R; Kawaguchi Y; Kamataki T
Effects of cyclosporin-A and D-penicillamine on the development of hepatitis and the production of antibody to protein disulfide isomerase in LEC rats.
Research communications in molecular pathology and pharmacology 1994;85(1):73-81.
1994: Nakajima M; Yokoi T; Mizutani M; Shin S; Kadlubar F F; Kamataki T
Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1994;3(5):413-21.
1994: Kashiyama E; Yokoi T; Itoh K; Itoh S; Odomi M; Kamataki T
Stereoselective S-oxidation of flosequinan sulfide by rat hepatic flavin-containing monooxygenase 1A1 expressed in yeast.
Biochemical pharmacology 1994;47(8):1357-63.
1994: Kashiyama E; Todaka T; Odomi M; Tanokura Y; Johnson D B; Yokoi T; Kamataki T; Shimizu T
Stereoselective pharmacokinetics and interconversions of flosequinan enantiomers containing chiral sulphoxide in rat.
Xenobiotica; the fate of foreign compounds in biological systems 1994;24(4):369-77.
1994: Nakura H; Itoh S; Kusano H; Ishizone H; Kamataki T
Activities of drug-metabolizing enzymes in the liver of Suncus murinus: possible lack of N-acetyltransferase activity in liver cytosol.
Pharmacology 1994;48(3):201-4.
1994: Sakuma T; Takai M; Yokoi T; Kamataki T
Molecular cloning and sequence analysis of hamster CYP2E1.
Biochimica et biophysica acta 1994;1217(2):229-31.
1994: Sakuma T; Masaki K; Itoh S; Yokoi T; Kamataki T
Sex-related differences in the expression of cytochrome P450 in hamsters: cDNA cloning and examination of the expression of three distinct CYP2C cDNAs.
Molecular pharmacology 1994;45(2):228-36.
1993: Hashimoto H; Toide K; Kitamura R; Fujita M; Tagawa S; Itoh S; Kamataki T
Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control.
European journal of biochemistry / FEBS 1993;218(2):585-95.
1993: Mori T; Kitamura R; Imaoka S; Funae Y; Matsubara T; Kamataki T
Increased CYP1A2 content and capacity to activate Glu-P-1 and Trp-P-2 in liver microsomes of scorbutic ODS rats.
Carcinogenesis 1993;14(12):2471-5.
1993: Yokoi T; Nagayama S; Kajiwara R; Kawaguchi Y; Horiuchi R; Kamataki T
Identification of protein disulfide isomerase and calreticulin as autoimmune antigens in LEC strain of rats.
Biochimica et biophysica acta 1993;1158(3):339-44.
1993: Okajima Y; Inaba N; Fukazawa I; Ota Y; Hirai Y; Sato N; Yamamoto G; Itahashi K; Kitada M; Kamataki T
Immunohistochemical and immunoelectron microscopic study of cytochrome P-450 of human fetal livers (P-450HFLa): implications for an onco-feto-placental enzyme.
Asia-Oceania journal of obstetrics and gynaecology / AOFOG 1993;19(3):329-41.
1993: Komori M; Kitamura R; Fukuta H; Inoue H; Baba H; Yoshikawa K; Kamataki T
Transgenic Drosophila carrying mammalian cytochrome P-4501A1: an application to toxicology testing.
Carcinogenesis 1993;14(8):1683-8.
1993: Itoh S; Tagawa S; Sawada M; Kamataki T
High susceptibility to aflatoxin B1 and benzo[a]pyrene of BALB3T3 A31-1-1 cells expressing monkey CYP1A1.
The Journal of toxicological sciences 1993;18(3):207-10.
1993: Itoh S; Kamataki T
Human Ah receptor cDNA: analysis for highly conserved sequences.
Nucleic acids research 1993;21(15):3578.
1993: Itoh K; Kimura T; Yokoi T; Itoh S; Kamataki T
Rat liver flavin-containing monooxygenase (FMO): cDNA cloning and expression in yeast.
Biochimica et biophysica acta 1993;1173(2):165-71.
1993: Sawada M; Kitamura R; Norose T; Kitada M; Itahashi K; Kamataki T
Metabolic activation of aflatoxin B1 by human placental microsomes.
The Journal of toxicological sciences 1993;18(2):129-32.
1993: Narita M; Nagai E; Hagiwara H; Aburada M; Yokoi T; Kamataki T
Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.
Xenobiotica; the fate of foreign compounds in biological systems 1993;23(1):5-10.
1993: Sawada M; Kitamura R; Ohgiya S; Kamataki T
Stable expression of guinea pig NADPH-cytochrome P450 reductase and monkey P4501A1 cDNAs in Chinese hamster cells: establishment of cell lines highly sensitive to aflatoxin B [corrected]
Archives of biochemistry and biophysics 1993;300(1):164-8.
1992: Komori M; Kikuchi O; Sakuma T; Funaki J; Kitada M; Kamataki T
Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450.
Biochimica et biophysica acta 1992;1171(2):141-6.
1992: Kitada M; Kato T; Ohmori S; Kamataki T; Itahashi K; Guengerich F P; Rikihisa T; Kanakubo Y
Immunochemical characterization and toxicological significance of P-450HFLb purified from human fetal livers.
Biochimica et biophysica acta 1992;1117(3):301-5.
1992: Kamataki T; Kitada M; Komori M; Yokoi T; Kitamura R
Human fetal liver cytochrome P-450: capacity to form genotoxic metabolites.
The Tohoku journal of experimental medicine 1992;168(2):89-95.
1992: Fukuta H; Ohi H; Uchida T; Komori M; Kitada M; Kamataki T
Toxicological significance of dog liver cytochrome P-450: examination with the enzyme expressed in Saccharomyces cerevisiae using recombinant expression plasmid.
Mutation research 1992;269(1):97-105.
1992: Nakura H; Itoh S; Kusano H; Ishizone H; Imaoka S; Funae Y; Yokoi T; Kamataki T
Decrease in the content of cytochrome P450IIE by fasting in liver microsomes of house musk shrew (Suncus murinus).
Biochemical pharmacology 1992;43(9):1907-10.
1992: Komori M; Kikuchi O; Kitada M; Kamataki T
Molecular cloning of monkey P450 1A1 cDNA and expression in yeast.
Biochimica et biophysica acta 1992;1131(1):23-9.
1992: Yanagimoto T; Itoh S; Muller-Enoch D; Kamataki T
Mouse liver cytochrome P-450 (P-450IIIAM1): its cDNA cloning and inducibility by dexamethasone.
Biochimica et biophysica acta 1992;1130(3):329-32.
1992: Itoh S; Yanagimoto T; Tagawa S; Hashimoto H; Kitamura R; Nakajima Y; Okochi T; Fujimoto S; Uchino J; Kamataki T
Genomic organization of human fetal specific P-450IIIA7 (cytochrome P-450HFLa)-related gene(s) and interaction of transcriptional regulatory factor with its DNA element in the 5' flanking region.
Biochimica et biophysica acta 1992;1130(2):133-8.
1992: Ubukata K; Ohi H; Kitada M; Kamataki T
A new form of cytochrome P-450 responsible for mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline in human livers.
Cancer research 1992;52(4):758-63.
1992: Mori T; Kitamura R; Imaoka S; Funae Y; Kitada M; Kamataki T
Examination for lipid peroxidation in liver microsomes of guinea pigs as a causal factor in the decrease in the content of cytochrome P-450 due to ascorbic acid deficiency.
Research communications in chemical pathology and pharmacology 1992;75(2):209-19.
1992: Kitamura R; Sato K; Sawada M; Itoh S; Kitada M; Komori M; Kamataki T
Stable expression of cytochrome P450IIIA7 cDNA in human breast cancer cell line MCF-7 and its application to cytotoxicity testing.
Archives of biochemistry and biophysics 1992;292(1):136-40.
1992: Sawada M; Kitamura R; Kamataki T
Stable expression of monkey cytochrome P-450IA1 cDNA in Chinese hamster CHL cells and its application for detection of mutagenicity of aflatoxin B1.
Mutation research 1992;265(1):23-9.
1991: Kashiwada M; Kitada M; Shimada T; Itahashi K; Sato K; Kamataki T
Purification and characterization of acidic form of glutathione S-transferase in human fetal livers: high similarity to placental form.
Journal of biochemistry 1991;110(5):743-7.
1991: Nagayama S; Kitamura R; Yokoi T; Kawaguchi Y; Kasai N; Takeichi N; Kobayashi H; Kamataki T
Occurrence of autoimmune antibodies to liver microsomal proteins in association with fulminant hepatitis in the LEC strain of rats.
Biochemical and biophysical research communications 1991;179(2):1134-40.
1991: Mori T; Kitada M; Imaoka S; Funae Y; Kamataki T
The in vitro effects of lipid peroxidation on the content of individual forms of cytochrome P-450 in liver microsomes of guinea-pigs.
Pharmacological research : the official journal of the Italian Pharmacological Society 1991;24(2):143-8.
1991: Nakura H; Ohi H; Miura T; Fujiwara T; Ishizone H; Yokoi T; Kitada M; Kamataki T
Formation of an antibacterial metabolite from a new macrolide compound 23-O-benzyl-5-mycaminosyl-tylonolide (TMC-101), by a hepatic microsomal drug-metabolizing enzyme system.
Journal of pharmacobio-dynamics 1991;14(7):377-83.
1991: Kitada M; Taneda M; Itahashi K; Kamataki T
Four forms of cytochrome P-450 in human fetal liver: purification and their capacity to activate promutagens.
Japanese journal of cancer research : Gann 1991;82(4):426-32.
1991: Kamataki T; Kitada M; Komori M
Molecular toxicology on cytochrome P-450 in human fetal livers.
The Journal of toxicological sciences 1991;16 Suppl 1():107-16.
1990: Uchida T; Komori M; Kitada M; Kamataki T
Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated beagle dogs.
Molecular pharmacology 1990;38(5):644-51.
1990: Kitada M; Taneda M; Ohta K; Nagashima K; Itahashi K; Kamataki T
Metabolic activation of aflatoxin B1 and 2-amino-3-methylimidazo[4,5-f]-quinoline by human adult and fetal livers.
Cancer research 1990;50(9):2641-5.
1989: Miura T; Iwasaki M; Komori M; Ohi H; Kitada M; Mitsui H; Kamataki T
Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics.
The Journal of antimicrobial chemotherapy 1989;24(4):551-9.
1989: Kitada M; Taneda M; Ohi H; Komori M; Itahashi K; Nagao M; Kamataki T
Mutagenic activation of aflatoxin B1 by P-450 HFLa in human fetal livers.
Mutation research 1989;227(1):53-8.
1989: Komori M; Nishio K; Fujitani T; Ohi H; Kitada M; Mima S; Itahashi K; Kamataki T
Isolation of a new human fetal liver cytochrome P450 cDNA clone: evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers.
Archives of biochemistry and biophysics 1989;272(1):219-25.
1989: Kitada M; Tsukidate K; Takeuchi J; Taneda M; Komori M; Ohi H; Itahashi K; Kamataki T
Immunochemical studies for the presence of P-450 HFLa, a form of cytochrome P-450 in human fetal livers in human hepatocellular carcinoma cells.
Journal of pharmacobio-dynamics 1989;12(6):341-4.
1989: Ohta K; Kitada M; Hashizume T; Komori M; Ohi H; Kamataki T
Purification of cytochrome P-450 from polychlorinated biphenyl-treated crab-eating monkeys: high homology to a form of human cytochrome P-450.
Biochimica et biophysica acta 1989;996(1-2):142-5.
1989: Miura T; Shimada H; Ohi H; Komori M; Kodama T; Kamataki T
Interspecies homology of cytochrome P-450: inhibition by anti-P-450-male antibodies of testosterone hydroxylases in liver microsomes from various animal species including man.
Japanese journal of pharmacology 1989;49(3):365-74.
1989: Kamataki T; Kitada M; Komori M; Inaba N
[Resistance to anticancer drugs in relation to cytochrome P-450]
Gan to kagaku ryoho. Cancer & chemotherapy 1989;16(3 Pt 2):605-10.
1989: Komori M; Nishio K; Ohi H; Kitada M; Kamataki T
Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450.
Journal of biochemistry 1989;105(2):161-3.
1989: Kitada M; Komori M; Ohi H; Imaoka S; Funae Y; Kamataki T
Form-specific degradation of cytochrome P-450 by lipid peroxidation in rat liver microsomes.
Research communications in chemical pathology and pharmacology 1989;63(2):175-88.
1989: Ohi H; Iwasaki M; Komori M; Miura T; Kitada M; Hayashi S; Kamataki T
Effects of serum testosterone level with buserelin on the activities of drug and testosterone hydroxylase and on the content of a male-specific form of cytochrome P-450 in male rats.
Biochemical pharmacology 1989;38(3):535-8.
1989: Komori M; Shimada H; Miura T; Kamataki T
Interspecies homology of liver microsomal cytochrome P-450. A form of dog cytochrome P-450 (P-450-D1) crossreactive with antibodies to rat P-450-male.
Biochemical pharmacology 1989;38(2):235-40.
1989: Ohta K; Motoya M; Komori M; Miura T; Kitada M; Kamataki T
A novel form of cytochrome P-450 in beagle dogs. P-450-D3 is a low spin form of cytochrome P-450 but with catalytic and structural properties similar to P-450d.
Biochemical pharmacology 1989;38(1):91-6.
1989: Ohi H; Toratani S; Komori M; Miura T; Kitada M; Kamataki T
Comparative study of cytochrome P-450 in liver microsomes. A form of monkey cytochrome P-450, P-450-MK1, immunochemically cross-reactive with antibodies to rat P-450-male.
Biochemical pharmacology 1989;38(2):361-5.
1988: Komori M; Hashizume T; Ohi H; Miura T; Kitada M; Nagashima K; Kamataki T
Cytochrome P-450 in human liver microsomes: high-performance liquid chromatographic isolation of three forms and their characterization.
Journal of biochemistry 1988;104(6):912-6.
1988: Kitada M; Igoshi N; Kamataki T; Itahashi K; Rikihisa T; Kanakubo Y
The proteins immunochemically related to P-450 HFLa, a major form of cytochrome P-450 in human fetal livers, are present in liver microsomes from various animal species.
Research communications in chemical pathology and pharmacology 1988;62(1):31-40.
1988: Kitada M; Igoshi N; Kamataki T; Itahashi K; Imaoka S; Komori M; Funae Y; Rikihisa T; Kanakubo Y
Immunochemical similarity of P-450 HFLa, a form of cytochrome P-450 in human fetal livers, to a form of rat liver cytochrome P-450 inducible by macrolide antibiotics.
Archives of biochemistry and biophysics 1988;264(1):61-6.
1988: Kamataki T; Komori M; Iwasaki M; Ohi H; Kitada M; Miura T; Ono K
Effects of muroctasin on the activities of drug metabolizing enzymes in liver microsomes of rats.
Arzneimittel-Forschung 1988;38(7A):1019-22.
1988: Miura T; Komori M; Iwasaki M; Kurozumi K; Ohta K; Ohmori S; Kitada M; Kamataki T
Sex-related difference in oxidative metabolism of testosterone and erythromycin by hamster liver microsomes.
FEBS letters 1988;231(1):183-6.
1987: Kitada M; Kamataki T; Itahashi K; Rikihisa T; Kanakubo Y
P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate.
The Journal of biological chemistry 1987;262(28):13534-7.
1987: Kitada M; Kamataki T; Itahashi K; Rikihisa T; Kanakubo Y
Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations.
Biochemical pharmacology 1987;36(4):453-6.
1985: Kitada M; Kamataki T; Itahashi K; Rikihisa T; Kato R; Kanakubo Y
Immunochemical examinations of cytochrome P-450 in various tissues of human fetuses using antibodies to human fetal cytochrome P-450, P-450 HFLa.
Biochemical and biophysical research communications 1985;131(3):1154-9.
1985: Kitada M; Kamataki T; Itahashi K; Rikihisa T; Kato R; Kanakubo Y
Purification and properties of cytochrome P-450 from homogenates of human fetal livers.
Archives of biochemistry and biophysics 1985;241(1):275-80.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Tetsuya Kamataki

Research Profile (preview)

Chemicals & Drugs

Anatomy

Concepts & Ideas

Living Beings

Genes & Molecular Sequences

Procedures

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Tetsuya Kamataki (preview)

All Publications